Advancing Cell & Gene Therapy: Resolution's $83M Investment for Macrophage Therapies
Thursday, 3 October 2024, 11:56
Investment in Macrophage Cell Therapies
Resolution has successfully secured $83 million through its Series B investment round. This funding will significantly propel the development of macrophage cell therapies aimed at treating inflammatory and fibrotic conditions.
Targeting Inflammatory and Fibrotic Indications
- Macrophage therapies are designed to modulate immune responses.
- They specifically target conditions related to the genito urinary system.
- Efforts in immunology are focused on enhancing patient care and treatment outcomes.
Future Implications
This investment underscores the growing importance of cell & gene therapy in developing innovative treatments. Resolution aims to set a new standard in therapeutic strategies by leveraging macrophage technology for various inflammatory diseases.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.